RSC-1255
RSC-1255 is a potent and selective Vacuolar H⁺-ATPase (V-ATPase) inhibitor that directly binds the mammalian V-ATPase complex with a Kd = 23 nM. RSC-1255 exhibits preferential cytotoxicity toward KRAS-mutant cancer cells, especially KRASG13D and KRASG12V cells. RSC-1255 blocks lysosomal acidification, autophagy, and macropinocytosis in cancer cells. RSC-1255 can be used for the study of KRAS-driven lung and colon cancers[1].
Product Specifications
CAS Number
2171015-78-2
UNSPSC
12352005
Target
Apoptosis; Autophagy; Proton Pump; Ras
Related Pathways
Apoptosis; Autophagy; GPCR/G Protein; MAPK/ERK Pathway; Membrane Transporter/Ion Channel
Field of Research
Cancer
Smiles
O=C(C1(C)N(C2=CC=C(C=C2F)F)N=C(C1C3=CC=C(Cl)O3)C4=C(F)C=C(F)C=C4)NCC5OCCN(C5)C
Molecular Formula
C27H25ClF4N4O3
Molecular Weight
564.96
References & Citations
[1]Tolani B, et al. Ras-mutant cancers are sensitive to small molecule inhibition of V-type ATPases in mice. Nat Biotechnol. 2022;40 (12) :1834-1844.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
K-Ras
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Polyclonal Antibody to Trafficking Protein Particle Complex 2 (TRAPPC2)